logo-loader
viewBenitec Biopharma

Benitec Biopharma receives $5.59M to advance gene silencing tech

The company’s therapeutics are used for treating chronic diseases.

shutterstock_366401786.jpg
The refund relates to research and development costs

Benitec Biopharma (ASX:BLT) has received a $5.59 million cash refund under the Federal Government’s R&D Tax Incentive Scheme.

The refund relates to the costs of research and development which qualify as eligible R&D expenditure under the Federal Government’s Scheme.

The funds will be used to advance Benitec’s human therapeutic programs in gene silencing.

Benitec is developing innovative therapeutics based on its patented gene-silencing technology called ddRNAi.

The company’s ddRNAi-based therapeutics are used for treating chronic and life-threatening conditions including hepatitis B, wet age-related macular degeneration and muscular dystrophy.

Furthermore, Benitec has received orphan drug designation in the European Union for its therapy ‘BB-301’ for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD).

OPMD is a rare inherited myopathy characterised by dysphagia (difficulty in swallowing), the loss of muscle strength, and weakness in multiple parts of the body.

The orphan drug designation provides regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition.

BB-301 is currently in preclinical development and Benitec plans to initiate IND (investigational new drug)-enabling studies later this year.

Benitec’s share price has increased by circa 45% since the beginning of this year, last trading at $0.16.

Quick facts: Benitec Biopharma

Price: 0.038 AUD

ASX:BLT
Market: ASX
Market Cap: $11.9 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Fertoz continues to plan for the future despite extremely...

Fertoz Ltd (ASX: FTZ) Executive Chairman Patrick Avery joined Steve Darling from Proactive Vancouver on Skype to discuss what has been a very tough weather year for the company. Even with that, Avery says the company has been very busy this year signing a number of distribution...

1 day, 19 hours ago

2 min read